Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A secondary offering put downward pressure on Moderna stock that will soon ease up. But wait for a dip toward $15 to buy shares.

Moderna Will Rebound, But Wait for a Dip Lower to Buy Shares

Moderna: A Reversal Of Fortunes Merits A Reality Check

Moderna announced the pricing of its secondary offering Wednesday, sending MRNA stock into a two-day dive that wiped out gains from last week related to its coronavirus vaccine efforts.

How A Two-Day Plunge Wiped Out This Biotech's Coronavirus Gains

A secondary offering causes dilution for the biotech.

Here's Why Moderna Slipped Lower Today

BioCryst Pharmaceuticals

Gilead Sciences

Inovio Pharmaceuticals

Novavax

These five biotechs are likely to remain on the volatile side this week, thanks to the novel-coronavirus threat.

Could These 5 Stocks Benefit From the Coronavirus Outbreak?

Shares of vaccine developer Moderna surged following the announcement.

Health Officials Say U.S. Coronavirus Vaccine is Making Good Progress

Shares of Moderna Inc. MRNA, +12.63% gained 12% in trading on Friday after a U.S.

Moderna's stock jumps as health officials say virus vaccine development has 'no glitches'

GW Pharmaceuticals

vTv Therapeutics

These drug stocks all have tremendous potential as these small companies work to treat widespread diseases in the U.S. and beyond.

3 Up-and-Coming Drug Stocks to Buy Now

Roche Holding AG

Some of the biopharma industry's biggest names are taking important steps to combat the world's latest public health emergency.

3 Big Drugmakers Are Taking On the Coronavirus

Regeneron Pharmaceuticals

Vir Biotechnology

Some biotech firms have been outperforming the market over the past few weeks on their treatment initiatives.

Investors rush into biotechs working on coronavirus vaccine

Alpha Pro Tech

As the coronavirus continues to be a threat to many parts of the world, these three stocks to buy could provide a bright spot in the crisis.

3 Coronavirus Stocks to Buy Until Crisis Is Averted

3 Reasons To Buy Moderna

If you wouldn't invest in flu vaccines, then you shouldn't view the ongoing coronavirus outbreak as a noteworthy investing opportunity.

Coronavirus Uncertainty Spreads, but Investors Should Remain Calm

Allied Healthcare Products

Cerus

Co-Diagnostics

Dyadic International Inc., DE

Lakeland Industries

NanoViricides

Monday morning brought a huge sell-off in the market as more and more people are concerned about the growing impact of this new coronavirus.

12 Stocks Surging That Could Help Treat or Fight Coronavirus

But it's important to separate the current panic from the real potential for these biotechs.

5 Biotech Stocks to Watch With the Coronavirus Scare

American Airlines

Delta Air Lines

Estee Lauder

LVMH Moet Hennessy Louis Vuitton

Royal Caribbean Cruises

United Continental Hlds

So far, 18 fatalities and more than 600 are affected by coronavirus in China and the virus is spreading across the boundary, spooking investors.

Coronavirus Spooks Global Markets: Winners and Losers

Several public and private organizations are coming forward to develop vaccines for the new coronavirus by funding developmental programs.

CEPI Grant, Government Aid Drive Coronavirus Focused Biotechs

The biotechnology company has been awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine for the fast-spreading illness.

Moderna to Begin Developing a Coronavirus Vaccine

Here we discuss three biotech stocks, which are likely to benefit in case there is an outbreak of coronavirus infection in China.

3 Biotech Stocks Likely to Gain as Coronavirus Spreads

Aethlon Medical

AstraZeneca

Cleveland BioLabs

Airlines, hotels, casinos and stocks linked to Wuhan, China, continue to fall as fear of the coronavirus deters international travel and all but halts activity in the virus epicenter.

13 Coronavirus-Related Stocks To Watch Amid Wuhan Outbreak

SPDR S&P Biotech ETF

Shares of vaccine makers rose sharply again on Thursday, amid rising concerns about the outbreak of a new coronavirus in Wuhan, China that has led the authorities to quarantine the city of 11 million.

Vaccine stocks rise sharply as coronavirus fears mounts

The company is working on a vaccine to protect against the latest coronavirus spreading from China, but investors are getting a little ahead of themselves.

Here's Why Moderna Stock Rose as Much as 10.8% Today

Moderna on Tuesday said it is working with U.S. government health agencies to develop a vaccine for the current strain of coronavirus that has killed nine and infected hundreds more in China.

Biotech firm Moderna is working on a vaccine for China's deadly coronavirus

Intuitive Surgical

KB Home

NortonLifeLock

Portola Pharmaceuticals

Take a look at the companies making headlines after the bell.

Stocks making the biggest moves after the bell: KB Home, Intuitive Surgical, NortonLifeLock and more

Akero Therapeutics Inc

Journey Medical Corp

Global Blood Therapeutics

On Dec. 17, GuruFocus reported that in a July article, Kiplinger identified Morphic Holding Inc.

News for Moderna Stock (MRNA)